5. CONCLUSION
This study has demonstrated that there is no clinically significant
difference in the levels of laboratory parameters, intensive care
admission, intubation requirement, rate of complications and most
importantly, survival rates in patients with CSD and those with cancer
who are infected with SARS-CoV-2, except in Hb and ferritin levels.
Additionally, in these patients, it was observed that SARS-CoV-2
infection had a clinically worse prognosis and fatal course compared to
those of normal population. Therefore, these patients should adhere more
strictly to general protection measures. It is recommended to plan the
treatment of patients with cancer and CSD infected with SARS-CoV-2 based
on a careful risk-benefit analysis by multidisciplinary teams.